Profile data is unavailable for this security.
About the company
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
- Revenue in CHF (TTM)617.07m
- Net income in CHF74.39m
- Incorporated2003
- Employees2.60k
- LocationYpsomed Holding AGBrunnmattstrasse 6BURGDORF 3401SwitzerlandCHE
- Phone+41 344244111
- Fax+41 344244122
- Websitehttps://www.ypsomed.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ambu A/S | 671.32m | 29.26m | 3.24bn | 5.20k | 125.41 | 5.28 | 27.98 | 4.83 | 0.8839 | 0.8839 | 20.26 | 21.00 | 0.7694 | 2.21 | 7.14 | 1,037,529.00 | 3.35 | 3.22 | 3.91 | 3.87 | 59.38 | 59.54 | 4.36 | 4.43 | 1.47 | 58.64 | 0.0907 | 25.41 | 12.90 | 13.84 | 39.88 | -5.81 | 2.06 | 0.00 |
| Getinge AB | 2.69bn | 135.56m | 3.37bn | 11.85k | 26.63 | 1.49 | 11.43 | 1.25 | 6.21 | 6.21 | 123.33 | 111.09 | 0.5937 | 2.51 | 7.30 | 2,861,487.00 | 3.01 | 5.31 | 4.00 | 6.98 | 45.80 | 47.83 | 5.07 | 8.69 | 0.5965 | 10.34 | 0.2629 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| SCHOTT Pharma AG & Co KgaA | 880.99m | 139.70m | 3.67bn | 4.65k | 26.18 | 5.14 | 18.65 | 4.16 | 1.00 | 1.00 | 6.31 | 5.10 | 0.7434 | 4.34 | 4.07 | 204,166.20 | 11.82 | -- | 16.42 | -- | 34.18 | -- | 15.90 | -- | 1.06 | -- | 0.1086 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
| Sectra AB | 145.11m | 35.85m | 3.95bn | 1.22k | 117.74 | 31.82 | 90.11 | 27.23 | 2.31 | 2.31 | 9.36 | 8.55 | 0.6136 | -- | 3.63 | 1,503,436.00 | 15.16 | 15.75 | 28.08 | 29.52 | 47.01 | 64.95 | 24.71 | 19.59 | -- | -- | 0.027 | 0.00 | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| Carl Zeiss Meditec AG | 1.92bn | 188.73m | 4.54bn | 4.95k | 23.99 | -- | -- | 2.37 | 2.28 | 2.28 | 23.14 | -- | -- | -- | -- | 428,397.90 | -- | 9.56 | -- | 11.72 | 55.12 | 57.84 | 9.84 | 13.15 | -- | -- | -- | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
| Ypsomed Holding AG | 617.07m | 74.39m | 4.75bn | 2.60k | 63.86 | 7.64 | 31.48 | 7.70 | 5.45 | 5.45 | 45.20 | 45.56 | 0.5828 | 5.28 | 5.46 | 268,759.60 | 7.03 | 4.41 | 11.60 | 6.81 | 35.44 | 27.26 | 12.06 | 7.38 | 0.5060 | 13.12 | 0.3434 | 20.50 | 10.25 | 3.86 | 52.83 | 5.44 | 8.64 | 29.46 |
| Amplifon SpA | 2.19bn | 144.78m | 4.89bn | 14.38k | 33.72 | 4.69 | 11.70 | 2.23 | 0.6898 | 0.6898 | 10.40 | 4.96 | 0.6255 | 20.32 | 10.83 | 164,118.00 | 4.13 | 4.31 | 6.24 | 5.81 | 23.55 | 59.01 | 6.61 | 7.28 | 0.4043 | 5.23 | 0.6064 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| ConvaTec Group PLC | 1.95bn | 135.87m | 5.30bn | 10.13k | 39.14 | 3.61 | 16.09 | 2.72 | 0.0592 | 0.0592 | 0.8505 | 0.6415 | 0.5965 | 2.47 | 5.89 | 172,594.00 | 4.15 | 2.36 | 4.74 | 2.73 | 55.96 | 55.03 | 6.96 | 4.34 | 1.27 | 2.96 | 0.4604 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| DiaSorin SpA | -92.88bn | -92.88bn | 5.41bn | 3.19k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 10.30 | -- | 11.50 | -- | 66.70 | -- | 21.25 | -- | -- | -- | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| Demant A/S | 2.79bn | 329.74m | 7.10bn | 21.50k | 21.53 | 5.95 | -- | 2.55 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 244.46k | 1.79% |
| UBS Asset Management Switzerland AGas of 05 Nov 2024 | 182.94k | 1.34% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 128.46k | 0.94% |
| Premier Fund Managers Ltd.as of 31 Jul 2024 | 117.96k | 0.86% |
| VV Verm�gensverwaltung AGas of 30 Aug 2024 | 90.28k | 0.66% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024 | 90.02k | 0.66% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 86.90k | 0.64% |
| GAM Investment Management (Switzerland) AGas of 31 Jul 2024 | 82.71k | 0.61% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 64.51k | 0.47% |
| Vontobel Asset Management AGas of 31 Jul 2024 | 59.55k | 0.44% |
